Cormorant Asset Management’s Agile Therapeutics AGRX Stock Holding History

Cormorant Asset Management’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-625	Closed	-$5.58M	–	58
2017 Q3	$5.58M	Hold	625	–	–	0.98%	31
2017 Q2	$4.69M	Hold	625	–	–	0.78%	38
2017 Q1	$4.01M	Buy	625 +343	+122%	+$1.72M	0.58%	45
2016 Q4	$3.21M	Hold	282	–	–	0.43%	50
2016 Q3	$3.94M	Hold	282	–	–	0.43%	58
2016 Q2	$4.29M	Buy	282 +3	+1%	+$41.1K	0.61%	46
2016 Q1	$3.46M	Buy	279 +188	+207%	+$2.43M	0.52%	47
2015 Q4	$1.78M	Hold	91	–	–	0.21%	63
2015 Q3	$1.23M	Hold	91	–	–	0.2%	69
2015 Q2	$1.56M	Hold	91	–	–	0.21%	64
2015 Q1	$1.69M	Buy	91 +16	+21%	+$280K	0.26%	57
2014 Q4	$921K	Hold	75	–	–	0.14%	64
2014 Q3	$1.09M	Hold	75	–	–	0.23%	59
2014 Q2	$1.31M	Buy	+75	New	+$1.09M	0.35%	50

Other funds holding AGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Cormorant Asset Management's AGRX Position: Q4 2017 in Review

Cormorant Asset Management sold out of Agile Therapeutics (AGRX) in Q4 2017, closing a stake of 625 shares — an estimated $5.58M sold.

Cormorant Asset Management first reported a position in AGRX in Q2 2014 and held it in 14 quarters. The position peaked at $5.58M in Q3 2017. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2017.

Cormorant Asset Management reported no remaining Agile Therapeutics position as of Q4 2017 after selling out during the quarter.
Cormorant Asset Management sold 625 Agile Therapeutics shares in Q4 2017, an estimated $5.58M.
Cormorant Asset Management first reported a position in Agile Therapeutics in Q2 2014 and held it in 14 quarters.
Cormorant Asset Management's Agile Therapeutics position peaked at $5.58M in Q3 2017.
45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2017.

Based on Cormorant Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.